Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190

Watchlist Manager
Zylox-Tonbridge Medical Technology Co Ltd Logo
Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190
Watchlist
Price: 22.9 HKD -3.46% Market Closed
Market Cap: 7.5B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+82%
Revenue
Forecast
+2%
Operating Income
Forecast
+11%
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Zylox-Tonbridge Medical Technology Co Ltd

Wall Street analysts forecast Zylox-Tonbridge Medical Technology Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Zylox-Tonbridge Medical Technology Co Ltd is 29.58 HKD with a low forecast of 28.28 HKD and a high forecast of 31.5 HKD.

Lowest Forecast
Wall Street Target
28.28 HKD
23% Upside
Average Forecast
Wall Street Target
29.58 HKD
29% Upside
Highest Forecast
Wall Street Target
31.5 HKD
38% Upside
Lowest
Price Target
28.28 HKD
23% Upside
Average
Price Target
29.58 HKD
29% Upside
Highest
Price Target
31.5 HKD
38% Upside
Zylox-Tonbridge Medical Technology Co Ltd Competitors:
Price Targets
S
SENS
Senseonics Holdings Inc
214% Upside
B
BIOBV
Biohit Oyj
25% Upside
6960
Fukuda Denshi Co Ltd
2% Upside
300760
Shenzhen Mindray Bio-Medical Electronics Co Ltd
25% Upside
S
SENS
Senseonics Holdings Inc
214% Upside
B
BIOBV
Biohit Oyj
25% Upside
6960
Fukuda Denshi Co Ltd
2% Upside
300760
Shenzhen Mindray Bio-Medical Electronics Co Ltd
25% Upside
M
305090
Micro Digital Co Ltd
96% Upside
V
100120
Vieworks Co Ltd
55% Upside
N
389650
NextBioMedical Co Ltd
13% Upside

Revenue
Forecast

Revenue Estimate
Zylox-Tonbridge Medical Technology Co Ltd

For the last 4 years the compound annual growth rate for Zylox-Tonbridge Medical Technology Co Ltd's revenue is 131%. The projected CAGR for the next 3 years is 32%.

131%
Past Growth
32%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Zylox-Tonbridge Medical Technology Co Ltd

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's operating income for the next 3 years is 69%.

N/A
Past Growth
69%
Estimated Growth
Estimates Accuracy
30%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Zylox-Tonbridge Medical Technology Co Ltd

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's net income for the next 3 years is 58%.

N/A
Past Growth
58%
Estimated Growth
Estimates Accuracy
18%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Zylox-Tonbridge Medical Technology Co Ltd's stock price target?
Price Target
29.58 HKD

According to Wall Street analysts, the average 1-year price target for Zylox-Tonbridge Medical Technology Co Ltd is 29.58 HKD with a low forecast of 28.28 HKD and a high forecast of 31.5 HKD.

What is Zylox-Tonbridge Medical Technology Co Ltd's Revenue forecast?
Projected CAGR
32%

For the last 4 years the compound annual growth rate for Zylox-Tonbridge Medical Technology Co Ltd's revenue is 131%. The projected CAGR for the next 3 years is 32%.

What is Zylox-Tonbridge Medical Technology Co Ltd's Operating Income forecast?
Projected CAGR
69%

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's operating income for the next 3 years is 69%.

What is Zylox-Tonbridge Medical Technology Co Ltd's Net Income forecast?
Projected CAGR
58%

The compound annual growth rate of Zylox-Tonbridge Medical Technology Co Ltd's net income for the next 3 years is 58%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 278,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.